The effect of natriuretic C-type peptide and its change over time on mortality in patients on haemodialysis or haemodiafiltration.
C-type natriuretic peptide
NTproCNP
convection volume
end-stage kidney disease
haemodiafiltration
haemodialysis
mortality
Journal
Clinical kidney journal
ISSN: 2048-8505
Titre abrégé: Clin Kidney J
Pays: England
ID NLM: 101579321
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
01
08
2019
accepted:
01
10
2019
entrez:
10
2
2021
pubmed:
18
11
2019
medline:
18
11
2019
Statut:
epublish
Résumé
C-type natriuretic peptide (CNP) and its co-product N-terminal proCNP (NTproCNP) have been associated with beneficial effects on the cardiovascular system. In prevalent dialysis patients, however, a relation between NTproCNP and mortality has not yet been investigated. Furthermore, as a middle molecular weight substance, its concentration might be influenced by dialysis modality. In a cohort of patients treated with haemodialysis (HD) or haemodiafiltration (HDF), levels of NTproCNP were measured at baseline and 6, 12, 24 and 36 months. The relation between serum NTproCNP and mortality and the relation between the 6-month rate of change of NTproCNP and mortality were analysed using Cox regression models. For the longitudinal analyses, linear mixed models were used. In total, 406 subjects were studied. The median baseline serum NTproCNP was 93 pmol/L and the median follow-up was 2.97 years. No relation between baseline NTproCNP or its rate of change over 6 months and mortality was found. NTproCNP levels remained stable in HD patients, whereas NTproCNP decreased significantly in HDF patients. The relative decline depended on the magnitude of the convection volume. In our study, levels of NTproCNP appear strongly elevated in prevalent dialysis patients. Second, while NTproCNP remains unaltered in HD patients, its levels decline in individuals treated with HDF, with the decline dependent on the magnitude of the convection volume. Third, NTproCNP is not related to mortality in this population. Thus NTproCNP does not seem to be a useful marker for mortality risk in dialysis patients.
Sections du résumé
BACKGROUND
BACKGROUND
C-type natriuretic peptide (CNP) and its co-product N-terminal proCNP (NTproCNP) have been associated with beneficial effects on the cardiovascular system. In prevalent dialysis patients, however, a relation between NTproCNP and mortality has not yet been investigated. Furthermore, as a middle molecular weight substance, its concentration might be influenced by dialysis modality.
METHODS
METHODS
In a cohort of patients treated with haemodialysis (HD) or haemodiafiltration (HDF), levels of NTproCNP were measured at baseline and 6, 12, 24 and 36 months. The relation between serum NTproCNP and mortality and the relation between the 6-month rate of change of NTproCNP and mortality were analysed using Cox regression models. For the longitudinal analyses, linear mixed models were used.
RESULTS
RESULTS
In total, 406 subjects were studied. The median baseline serum NTproCNP was 93 pmol/L and the median follow-up was 2.97 years. No relation between baseline NTproCNP or its rate of change over 6 months and mortality was found. NTproCNP levels remained stable in HD patients, whereas NTproCNP decreased significantly in HDF patients. The relative decline depended on the magnitude of the convection volume.
CONCLUSIONS
CONCLUSIONS
In our study, levels of NTproCNP appear strongly elevated in prevalent dialysis patients. Second, while NTproCNP remains unaltered in HD patients, its levels decline in individuals treated with HDF, with the decline dependent on the magnitude of the convection volume. Third, NTproCNP is not related to mortality in this population. Thus NTproCNP does not seem to be a useful marker for mortality risk in dialysis patients.
Identifiants
pubmed: 33564441
doi: 10.1093/ckj/sfz156
pii: sfz156
pmc: PMC7857796
doi:
Types de publication
Journal Article
Langues
eng
Pagination
375-381Informations de copyright
© The Author(s) 2019. Published by Oxford University Press on behalf of ERA-EDTA.
Références
Neurosci Lett. 1993 Sep 3;159(1-2):25-8
pubmed: 8264972
Eur J Heart Fail. 2014 Sep;16(9):958-66
pubmed: 25082741
Biochem Biophys Res Commun. 2001 Aug 24;286(3):513-7
pubmed: 11511088
Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4016-21
pubmed: 11259675
Hypertension. 1997 Jun;29(6):1296-302
pubmed: 9180632
Br J Pharmacol. 1999 Sep;128(1):206-12
pubmed: 10498853
Clin Chim Acta. 2015 Mar 30;443:108-13
pubmed: 25512164
Kidney Int. 2006 Jan;69(1):152-6
pubmed: 16374436
Am J Physiol Endocrinol Metab. 2009 Dec;297(6):E1339-48
pubmed: 19808910
Mol Biol Rep. 2013 Feb;40(2):1429-41
pubmed: 23073778
Eur J Vasc Endovasc Surg. 2012 Jun;43(6):649-54
pubmed: 22421372
Curr Control Trials Cardiovasc Med. 2005 May 20;6(1):8
pubmed: 15907201
Endocrinology. 1993 Dec;133(6):3038-41
pubmed: 8243333
Clin Chem. 2017 Jan;63(1):316-324
pubmed: 28062626
Clin Endocrinol (Oxf). 2013 May;78(5):783-9
pubmed: 22963390
J Am Soc Nephrol. 2012 Jun;23(6):1087-96
pubmed: 22539829
Hypertension. 2015 Jun;65(6):1187-94
pubmed: 25895587
Curr Pharm Des. 2010;16(37):4080-8
pubmed: 21247399
J Clin Invest. 1992 Sep;90(3):1145-9
pubmed: 1522222
Proc Natl Acad Sci U S A. 2005 Oct 4;102(40):14452-7
pubmed: 16179391
Circ Res. 2002 Nov 29;91(11):1063-9
pubmed: 12456493
Mol Cell Endocrinol. 1999 Jun 25;152(1-2):11-9
pubmed: 10432219
Nephrol Dial Transplant. 2016 Jun;31(6):978-84
pubmed: 26492924
Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1426-31
pubmed: 12552127
Clin Sci (Lond). 1994 Sep;87(3):319-22
pubmed: 7955908